Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Parathyroid disorders, including hyperparathyroidism and hypoparathyroidism, are relatively common endocrine conditions affecting the regulation of calcium levels in the body. Hyperparathyroidism is more prevalent, with primary hyperparathyroidism being the most common form, affecting approximately 1 in 1,000 people. Hypoparathyroidism, although less common, still contributes to a substantial patient population, with an estimated prevalence of 37 per 100,000 individuals.
The availability of specialized endocrine clinics, knowledgeable healthcare providers, and complete diagnostic services is critical to successful parathyroid disorders’ management. Healthcare infrastructure disparities across regions affects patient access to early diagnosis, treatment, and follow-up, thus pointing to the need for better healthcare resources and services in underserved areas.
The continued research projects that are aimed at understanding the pathogenesis of parathyroid disorders, identifying new therapeutic targets and evaluating treatment effectiveness provide innovation in the market. Collaborative projects involving academic institutions, drug entities, and regulatory bodies increase the rate of development and marketing of new treatment modalities for parathyroid disorders.
The parathyroid disorders market is primarily regulated by regulatory agencies that have been charged with the responsibility of approving and overseeing diagnostic tests, pharmaceuticals, and medical devices such as the FDA in the United States and the European Medicines Agency (EMA) in Europe. Adherence to regulatory standards and guidelines is crucial for participants in the market to guarantee that products and therapies related to parathyroid disorder are safe and effective.
Among the trends, global demographic ones as aging of population and the emergence of chronic kidney diseases play particulate role in the growing of incidence and prevalence of parathyroid disorders.
Parathyroid disorders associated indirect costs related to loss of productivity, disability, and care-giver burden also enhances the economic impact on patients, families, and health systems.
Multidisciplinary care models involving endocrinologists, surgeons, radiologists, nephrologists, and other specialists are essential for providing comprehensive and coordinated care for patients with parathyroid disorders. Collaborative care models optimize treatment outcomes, improve patient satisfaction, and enhance quality of life by addressing the multifaceted needs of individuals with parathyroid disorders.
Parathyroid Disorders Market Highlights:
Parathyroid Disorders Market Scenario:
The Parathyroid Disorders Market Size was valued at USD 1.98 Billion in 2023. The Global Parathyroid Disorders industry is projected to grow from USD 2.15 Billion in 2024 to USD 3.86 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.69% during the forecast period (2024 - 2032). Parathyroid glands produce and secrete a parathyroid hormone which is involved in regulation of calcium and phosphorus metabolism. Hyperparathyroidism and Hypoparathyroidism are the two most common parathyroid disorders. The hyperparathyroidism is characterized by an excessive secretion of parathyroid hormone. The most common signs and symptoms of the disorder include kidney stones, bone and joint pain, fragile bones, weakness.
According to a study published in the Turkish Journal of Trauma and Emergency Surgery in 2016, it is found that hyperparathyroidism is the third most common clinical endocrine disorder with a prevalence between 0.1–1.0%, and an incidence of around 28 cases per 100,000 individuals. It also reported that the incidence rate is highest between 50 and above age group i.e. the condition is affecting 2% of the population aged 55 years or older.
Notably, rising prevalence of parathyroid disorders and growing geriatric population are the key factors driving the parathyroid disorders market.
Various other factors such as increasing incidences of parathyroid disorders, increasing government assistance, rising healthcare expenditures, improving regulatory framework, and rising funding and reimbursement policies are continuously contributing to the growth of the parathyroid disorders market. According to the data suggested by Eurostat, it is observed that among the EU Member States, the highest value of healthcare expenditure was recorded in Germany in 2014 i.e. EUR 321 billion, which is further followed by France with EUR 237 billion, and the United Kingdom with EUR 223 billion.
Despite these drivers, there are some issues associated with parathyroid disorders market. Some of the challenges include less research and development funding, side-effects of treatment, the presence of misbranded and spurious drugs, expiration of patented drugs and poor healthcare system in low and middle-income countries may hinder the growth of the market to an extent.
Intended Audience:
- Pharmaceutical Companies
- Research and Development (R&D) Companies
- Medical Device Companies
- Diagnostic Laboratories
- Government Research Institute
- Academic Institutes and Universities
Segmentation
The parathyroid disorders market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of the type, the parathyroid disorders market is classified as hyperparathyroidism (HPT), parathyroid cancer, and hypoparathyroidism. The hyperparathyroidism is further segmented into primary hyperparathyroidism, secondary hyperparathyroidism, and tertiary hyperparathyroidism.
On the basis of the diagnosis, the parathyroid disorders market is classified as blood tests, imaging tests, and urine tests. The imaging tests is further sub-segmented into CT or CAT (computed axial tomography) scans, MRI (magnetic resonance imaging) scans, X-ray, ultrasound, bone density test, and sestamibi scan.
On the basis of the treatment, the parathyroid disorders market is classified as surgery, radiation therapy, drugs, and others. The drugs segment is further sub-segmented into calcimimetics, hormone replacement therapy, and bisphosphonates.
On the basis of the end-user, the parathyroid disorders market is segmented into hospitals & clinics, diagnostic centers, drug stores, pharmacies, and others.
Regional Analysis:
The Americas dominate the parathyroid disorders market owing to the rising prevalence of parathyroid disorders and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.
Europe holds the second position in the parathyroid disorders market. It is expected that the support provided by the government bodies for research & development and improvement in the reimbursement policies in the healthcare is likely to drive the market of the European region.
The Asia Pacific region is the fastest growing parathyroid disorders market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.
The Middle East & Africa holds the least market share due to lack of technical knowledge and poor medical facilities.
Key Players
Some of the key players in the parathyroid disorders market are Abbott Laboratories, Alcon Laboratories, Inc., Amgen Inc., Bayer Healthcare, Becton, Dickinson and Company, Eli Lilly, Ethicon, Inc., Genentech, Medtronic, Merck, Mylan Laboratories, Novartis, Novo Nordisk, Pfizer, Roche, Smith & Nephew plc, Stryker, Teva Pharmaceutical Industries Ltd., Zimmer Biomet Holdings, Inc., and others.
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
